|
WO2011097447A2
|
|
Production of recombinant virus
|
|
US2009214637A1
|
|
Novel Gene Therapy Approach For Treating The Metabolic Disorder Obesity
|
|
EP2211909A2
|
|
A novel gene therapy approach for treating the metabolic disorder obesity
|
|
WO2008097875A1
|
|
Novel methods for treating neurodegenerative disorders
|
|
US2009098631A1
|
|
Novel glutamic acid decarboxylase (GAD) proteins and methods of use
|
|
CA2610164A1
|
|
Novel glutamic acid decarboxylase (gad) chimera and methods of use
|
|
WO2006116220A1
|
|
Use of adenoviral protein e1b-19k in degenerative disorders
|
|
CA2584986A1
|
|
Use of apoptosis inhibiting compounds in degenerative neurological disorders
|
|
US2006228776A1
|
|
PINK-1 promoter
|
|
AU2004101085A4
|
|
Glutamic acid decarboxylase (GAD)based delivery systems
|
|
US7723288B2
|
|
Methods and compositions for the treatment of neurological disease
|
|
US2005025746A1
|
|
Glutamic acid decarboxylase (GAD) based delivery systems
|
|
WO2004069269A1
|
|
Method for making a cell more susceptible for a compound by expressing the protein, on which said compound acts, in said cell
|
|
AU8327801A
|
|
Replication competent aav helper functions
|
|
WO0189583A2
|
|
Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
|
|
US6329181B1
|
|
Helper functions for recombinant vector production
|
